Employees: 214
Size Philogen (PHIL.MI) is an Italy Health Care company (Pharmaceuticals: Major) with a market value of $672M, the 95th largest of 121 Italy companies the cockpit tracks. Shares closed at €20.95 on 18 Nov 2026.
Performance Over six months the shares fell 10.8%, against -6.0% for the median peer and +3.1% for the Italy market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 294.9% over the last twelve months (peer median +10.2%); the operating margin is 78.8% (peer median 9.7%).
Valuation It trades at 10.1× forward earnings against a peer median of 21.5× (2nd cheapest of 9).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €311M | €314M | €74.0M | €23.1M | €23.7M |
| Revenue growth | — | +325% | +220% | -2% | — |
| Gross profit | €263M | €272M | €39.5M | -€6.36M | €914,000 |
| EBITDA | €250M | €256M | €38.0M | -€7.19M | -€561,000 |
| Net income | €225M | €230M | €45.3M | -€6.16M | -€5.38M |
| Free cash flow | €268M | €268M | €40.4M | -€8.80M | -€8.58M |
| Capital expenditure | €2.20M | €3.63M | €2.41M | €5.86M | €4.21M |
| Total debt | n/a | €10.9M | €11.5M | €14.9M | €15.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PHIL.MI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.2% | -3.7% | 11th highest of 21 |
| 6-month return | -10.8% | -6.0% | 10th lowest of 21 |
| Distance from 52-week high | -19.4% | -32.5% | 6th highest of 21 |
| Revenue growth (TTM) | +294.9% | +10.2% | 3rd highest of 18 |
| Operating margin | 78.8% | 9.7% | 3rd highest of 18 |
| Forward P/E | 10.1× | 21.5× | 2nd cheapest of 9 |
| EV / EBITDA | 1.1× | 7.2× | cheapest of 9 |
| Net debt / EBITDA | -1.3× | -1.3× | 5th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 10.1× | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 112.1× | 31.9% | +19.8% |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 24.9× | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | n/a | -8.3% | -2.8% |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | n/a | n/a | n/a |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 9.1× | n/a | n/a |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 18.0× | -1.6% | -1.8% |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | n/a | 25.2% | +10.3% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 32.2× | 27.1% | +31.4% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | n/a | 4.0% | +5.3% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 79.7× | 9.1% | +7.9% |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | n/a | 36.3% | +16.2% |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 16.1× | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | n/a | n/a | n/a |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | n/a | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | n/a | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 13.7× | -4.8% | +6.4% |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |